Seelos Therapeutics Inc (SEEL)

[value1008]

Carlo, i agree that the next several months (i'd say 4-8 mos.) are crucially important for APRI....

Btw, thinking about cash, if some significant milestone payments come in, product launches and there is realistic-looking prospect of good revenues for Vitaros, and then any excitement from pharma company or companies over partnering for FemProx develops, then this APRI pps should finally soar.

And then as a result there's always the prospect of further income from warrants getting exercised if pps soars up to $6, $7 or higher.

Warrant situation:
From offering on Feb 8, 2012 there seem to be 2.5M warrants exercisable at 5.25/share.
From offering on May 22, 2013 (PR'd on 5/23) there are 3.45M warrants exercisable at 3.40/share.

This would bring in $13.12M and $11.73M if all warrants exercised.

But some hefty milestone payments and any upfront licensing fees from new partners on Vitaros and/or FemProx would sure help the cash situation!